Our client was Director of Economics and Reimbursement for a small US-based pharmaceutical company. The company wished to ‘re-launch’ their intravenous antihypertensive agent in the US to show its value in specific neurological indications that had not been the focus of clinical development studies. They asked us to prepare a Value Dossier focused on these indications.
The client challenge
Payers and budget-holders were not prepared to pay a higher price for this drug in situations where generic intravenous antihypertensives were seen to be adequate. It was necessary to translate the original pharmacokinetic properties of this product into clinical benefits and define the clinical situations in which these benefits made a difference to patient outcomes and economic outcomes.
How we helped
We worked closely with the client team to define potential value propositions for the product in different clinical situations and researched the evidence for poor outcomes with current management in each situation. This included participating in workshops with KOLs and collaborating with the team conducting analyses of hospital databases to look at clinical and cost outcomes associated with use of different antihypertensives in each of the neurological indications. We then devised a structure for the Value Dossier that referred to a core set of information on the product and provided data on each indication in terms of the rationale for use and the projected clinical and economic benefits that derived from each feature of the product.
The client team was delighted with our collaboration and the end product and asked us to write a Core Value Dossier for Europe for the cardiovascular indications of the product.